Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

• Published in: Circulation (New York, N.Y.) Vol. 147; no. 16; pp. 1192 - 1203
• Main Authors: Gaba, Prakriti, O’Donoghue, Michelle L., Park, Jeong-Gun, Wiviott, Stephen D., Atar, Dan, Kuder, Julia F., Im, KyungAh, Murphy, Sabina A., De Ferrari, Gaetano M., Gaciong, Zbigniew A., Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose, Schiele, François, Mach, François, Flores-Arredondo, Jose H., López, J. Antonio G., Elliott-Davey, Mary, Wang, Bei, Monsalvo, Maria Laura, Abbasi, Siddique, Giugliano, Robert P., Sabatine, Marc S.
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 18.04.2023
• Subjects: Anticholesteremic Agents - adverse effects; Atherosclerosis - drug therapy; Cardiovascular Diseases - drug therapy; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Myocardial Infarction - epidemiology; PCSK9 Inhibitors; Proprotein Convertase 9; Stroke - epidemiology; Treatment Outcome; atherosclerosis; cholesterol; lipoproteins, LDL; cardiovascular diseases

Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown. In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inh...